TCRT vs. MEIP, SLGL, BNTC, SYBX, NNVC, RNXT, GLYC, KALA, BIVI, and GLTO
Should you be buying Alaunos Therapeutics stock or one of its competitors? The main competitors of Alaunos Therapeutics include MEI Pharma (MEIP), Sol-Gel Technologies (SLGL), Benitec Biopharma (BNTC), Synlogic (SYBX), NanoViricides (NNVC), RenovoRx (RNXT), GlycoMimetics (GLYC), KALA BIO (KALA), BioVie (BIVI), and Galecto (GLTO). These companies are all part of the "pharmaceutical preparations" industry.
Alaunos Therapeutics (NASDAQ:TCRT) and MEI Pharma (NASDAQ:MEIP) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their community ranking, institutional ownership, dividends, media sentiment, valuation, analyst recommendations, profitability, earnings and risk.
MEI Pharma has higher revenue and earnings than Alaunos Therapeutics.
MEI Pharma has a net margin of 39.06% compared to Alaunos Therapeutics' net margin of 0.00%. MEI Pharma's return on equity of 48.32% beat Alaunos Therapeutics' return on equity.
27.7% of Alaunos Therapeutics shares are held by institutional investors. Comparatively, 52.4% of MEI Pharma shares are held by institutional investors. 6.2% of Alaunos Therapeutics shares are held by company insiders. Comparatively, 3.9% of MEI Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
MEI Pharma received 369 more outperform votes than Alaunos Therapeutics when rated by MarketBeat users. Likewise, 60.74% of users gave MEI Pharma an outperform vote while only 58.33% of users gave Alaunos Therapeutics an outperform vote.
Alaunos Therapeutics has a beta of -0.26, meaning that its share price is 126% less volatile than the S&P 500. Comparatively, MEI Pharma has a beta of 0.82, meaning that its share price is 18% less volatile than the S&P 500.
In the previous week, Alaunos Therapeutics and Alaunos Therapeutics both had 2 articles in the media. Alaunos Therapeutics' average media sentiment score of 0.69 beat MEI Pharma's score of 0.00 indicating that Alaunos Therapeutics is being referred to more favorably in the media.
MEI Pharma has a consensus price target of $7.00, indicating a potential upside of 122.22%. Given MEI Pharma's higher probable upside, analysts clearly believe MEI Pharma is more favorable than Alaunos Therapeutics.
Summary
MEI Pharma beats Alaunos Therapeutics on 10 of the 12 factors compared between the two stocks.
Get Alaunos Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for TCRT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TCRT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Alaunos Therapeutics Competitors List
Related Companies and Tools
